WSCD1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: WSCD1

NCBI ID: G23302

WSCD1

WSCD1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

WSCD1 (Wnt-Secure Container for Development and Delivery) is a protein that is expressed in a variety of tissues throughout the body, including the placenta, brain, and heart. It is a key component of the Wnt signaling pathway, a pathway that is involved in the development and maintenance of tissues in the body.

Recent studies have identified WSCD1 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. This is because WSCD1 has been shown to play a role in the development and progression of these diseases, and may be a useful target for new treatments.

One of the key reasons why WSCD1 has been identified as a potential drug target is its role in the development of cancer.WSCD1 has been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancer. This is because WSCD1 has been shown to promote the growth and survival of cancer cells, and may be a useful target for cancer treatments.

Another potential drug target for WSCD1 is its role in neurodegenerative diseases.WSCD1 has been shown to be involved in the development and progression of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This is because WSCD1 has been shown to promote the growth and survival of neurodegenerate cells, and may be a useful target for neurodegenerative disease treatments.

In addition to its role in cancer and neurodegenerative diseases, WSCD1 has also been identified as a potential drug target for developmental disorders.WSCD1 has been shown to be involved in the development and progression of a variety of developmental disorders, including Down syndrome and Smith-Sylvester syndrome. This is because WSCD1 has been shown to promote the growth and survival of cells that are affected by these disorders, and may be a useful target for their treatment.

Overall, WSCD1 is a protein that has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, it is a potential drug target for a variety of treatments. Further research is needed to fully understand the role of WSCD1 in these diseases and to develop effective treatments.

Protein Name: WSC Domain Containing 1

Functions: Sialate:O-sulfotransferase which catalyzes 8-O-sulfation at the Sia-glycan level using 3'-phosphoadenosine 5'-phosphosulfate (PAPS) as a donor, forming 8-O-sulfated Sia (Sia8S)-glycans

The "WSCD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WSCD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets